Ilka Mathar

Wuppertal, NW 42096, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Runcaciguat activates soluble guanylyl cyclase via the histidine essential for heme binding and nitric oxide activation.

Runcaciguat activates soluble guanylyl cyclase via the histidine essential for heme binding and nitric oxide activation.

Journal: Biochemical pharmacology

Published: August 27, 2024

TRPC5 controls the adrenaline-mediated counter regulation of hypoglycemia.

TRPC5 controls the adrenaline-mediated counter regulation of hypoglycemia.

Journal: The EMBO journal

Published: June 14, 2024

The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats.

The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats.

Journal: International journal of molecular sciences

Published: July 14, 2023

Activating soluble guanylyl cyclase attenuates ischemic kidney damage.

Activating soluble guanylyl cyclase attenuates ischemic kidney damage.

Journal: Kidney international

Published: June 19, 2023

OCaR1 endows exocytic vesicles with autoregulatory competence by preventing uncontrolled Ca2+ release, exocytosis, and pancreatic tissue damage.

OCaR1 endows exocytic vesicles with autoregulatory competence by preventing uncontrolled Ca2+ release, exocytosis, and pancreatic tissue damage.

Journal: The Journal of clinical investigation

Published: February 15, 2023

Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution.

Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution.

Journal: Cell reports. Medicine

Published: October 17, 2022

Urinary miRNA Profiles in Chronic Kidney Injury-Benefits of Extracellular Vesicle Enrichment and miRNAs as Potential Biomarkers for Renal Fibrosis, Glomerular Injury, and Endothelial Dysfunction.

Urinary miRNA Profiles in Chronic Kidney Injury-Benefits of Extracellular Vesicle Enrichment and miRNAs as Potential Biomarkers for Renal Fibrosis, Glomerular Injury, and Endothelial Dysfunction.

Journal: Toxicological sciences : an official journal of the Society of Toxicology

Published: March 04, 2022

Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease.

Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: August 09, 2021

Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy.

Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy.

Journal: International journal of molecular sciences

Published: April 29, 2021

Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.

Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.

Journal: American journal of nephrology

Published: February 11, 2021

Control of Insulin Release by Transient Receptor Potential Melastatin 3 (TRPM3) Ion Channels.

Control of Insulin Release by Transient Receptor Potential Melastatin 3 (TRPM3) Ion Channels.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: October 28, 2020

Loss of smooth muscle CYB5R3 amplifies angiotensin II-induced hypertension by increasing sGC heme oxidation.

Loss of smooth muscle CYB5R3 amplifies angiotensin II-induced hypertension by increasing sGC heme oxidation.

Journal: JCI insight

Published: March 28, 2019

Showing 1-12 of 24

Last Updated: 09/26/2026